FDAが少なくとも1回の治療歴を有する慢性リンパ性白血病(CLL)あるいは小リンパ球性リンパ腫(SLL)患者を適応としてvenetoclaxを承認【FDA】

FDA approves venetoclax for CLL or SLL, with or without 17 p deletion, after one prior therapy


On June 8, 2018, the Food and Drug Administration granted regular approval to venetoclax (VENCLEXTA, AbbVie Inc. and Genentech Inc.) for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion, who have received at least one prior therapy.

  

コメント

Leave a comment

Your email address will not be published.


*